Prochlorperazine-Induced Neuroleptic Malignant Syndrome: Clinical Insights from a Recent Case Report

Study Background and Research Question

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening neurologic emergency most often associated with antipsychotic drug exposure. While the majority of documented cases involve classic or atypical antipsychotics, recent clinical observations have brought attention to the potential for NMS to arise from other dopamine-modulating agents, including antiemetics such as prochlorperazine. The reference study led by Zong-Jun Tee at Kaohsiung Medical University Hospital (DOI) addresses the core question: How does prochlorperazine, at standard doses, precipitate NMS in a geriatric patient with multiple comorbidities, and what are the diagnostic and therapeutic challenges faced in such atypical presentations?

Key Innovation from the Reference Study

The principal innovation of this case report lies in its thorough documentation of an NMS episode induced by a commonly prescribed antiemetic, prochlorperazine, rather than a classic neuroleptic. The study provides a detailed clinical timeline and diagnostic pathway, demonstrating that NMS can occur even in the absence of hallmark laboratory abnormalities. This work expands the clinical spectrum of NMS triggers and underscores the need for heightened vigilance when using dopamine antagonists in vulnerable populations, particularly older adults with comorbid conditions.

Methods and Experimental Design Insights

This single-patient case study adopted a comprehensive clinical methodology. Data collection encompassed:

• Systematic review of the patient's medication history, including recent exposure to prochlorperazine.
• Detailed physical and neurological examinations, capturing symptoms such as rigidity, altered consciousness, and autonomic instability.
• Serial laboratory assessments (white blood cell count, creatine phosphokinase, blood ammonia, blood gas, and electrolytes).
• Imaging (emergent brain CT) and cerebrospinal fluid analysis to exclude differential diagnoses such as CNS infection or acute vascular events.
• Continuous monitoring during hospitalization, including electroencephalography (EEG) to rule out seizure activity.

Therapeutic intervention included the administration of intravenous lorazepam and oral amantadine, with careful tapering and follow-up during outpatient care.

Core Findings and Why They Matter

The case involved a 76-year-old man presenting with fever, acute mental status changes, autonomic instability, and generalized "leadpipe" rigidity—a constellation of symptoms fulfilling the clinical criteria for NMS. Notably, laboratory results did not reveal the pronounced leukocytosis or highly elevated creatine phosphokinase (CPK) levels often described in NMS, with CPK peaking at 454 U/L (modestly elevated for NMS). Brain imaging and CSF analysis excluded alternative causes such as infection or acute stroke. The diagnostic process relied on exclusion and the presence of classic clinical signs following prochlorperazine exposure, emphasizing the need for high clinical suspicion even when laboratory markers are equivocal. Therapeutic management with lorazepam and amantadine led to rapid clinical improvement, including resolution of fever, normalization of mental status, and abatement of rigidity. The case illustrates both the potential for prochlorperazine to precipitate NMS and the importance of prompt withdrawal of the offending agent, supportive care, and targeted pharmacotherapy. As highlighted in the reference report, early recognition and tailored intervention are critical to preventing morbidity and mortality.

Comparison with Existing Internal Articles

Recent internal resources provide a mechanistic backdrop for understanding drug-induced neurological emergencies. For example, the article "Morin: Beyond Antioxidant—Mechanistic Insights for Neurology" explores the neuroprotective and mitochondrial effects of Morin, a natural flavonoid. Although Morin is not directly implicated in NMS, its mechanisms—such as modulation of oxidative stress and mitochondrial energy metabolism—are relevant to models of neuronal injury and metabolic dysfunction seen in acute syndromes like NMS. Similarly, "Prochlorperazine-Induced Neuroleptic Malignant Syndrome: Case Insights" provides additional context and analysis of the diagnostic pitfalls and management strategies described in the primary study. Of particular interest is the potential for anti-inflammatory flavonoids like Morin to serve as adjuncts in research models investigating neuroleptic toxicity, oxidative stress, and mitochondrial compromise. Internal reviews (see also Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one)) underline Morin's utility as a biochemical probe and mechanistic tool in the context of diabetes and neurodegenerative research, which share overlapping pathobiological features with NMS, such as mitochondrial dysfunction and oxidative stress.

Limitations and Transferability

While the case report provides a compelling narrative and practical guidance, its single-patient design inherently limits generalizability. The absence of typical laboratory markers in this case highlights the heterogeneity of NMS presentations, complicating diagnostic algorithms and suggesting that reliance on laboratory criteria alone may delay critical interventions. Additionally, the specific pathophysiological cascade by which prochlorperazine induces NMS in susceptible individuals remains incompletely understood, underscoring the need for mechanistic studies and translational modeling. Transferability of findings is most immediate to clinicians managing polypharmacy in older adults, but the implications extend to researchers seeking to develop more nuanced in vitro and in vivo models of drug-induced neurotoxicity. The integration of mechanistic probes—such as flavonoids with antioxidant and mitochondrial modulating properties—may help delineate the cellular events underpinning syndromes like NMS, especially in the context of comorbid metabolic disease.

Protocol Parameters

• Drug challenge: Prochlorperazine at 5 mg twice daily for 2 weeks; monitor for NMS symptoms when modeling dopamine antagonist exposure in aged or metabolically compromised rodents or cell lines.
• Clinical assessment: Monitor for fever, rigidity, altered mental status, and autonomic instability. Laboratory analysis should include CPK, white blood cell count, and electrolytes, but note that absence of classic abnormalities does not exclude NMS.
• Therapeutic modeling: Consider benzodiazepines and dopaminergic agents (e.g., amantadine) for intervention studies.
• Adjunctive research tools: Antioxidant and mitochondrial probes such as Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) may be used to study oxidative and metabolic sequelae in NMS models.

Research Support Resources

To facilitate translational research on drug-induced neurotoxicity, researchers may consider integrating Morin (SKU C5297), a characterized natural flavonoid with antioxidant, anti-inflammatory, and mitochondrial modulatory effects. According to the product information, Morin is suitable for in vitro and in vivo modeling of oxidative stress and mitochondrial dysfunction, and also functions as a fluorescent aluminum ion probe. For studies requiring precise investigation of pathways such as inhibition of adenosine 5′-monophosphate deaminase or the evaluation of cardioprotective and neuroprotective agents, Morin offers a well-characterized experimental tool. Researchers are advised to follow recommended storage and solubility guidelines to ensure compound integrity during experimental use.